We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst ...

Regeneron acquires 23andMe for $256 million, raising privacy concerns over genetic data use amid promises of continued consumer services and protectio ... A shift in the DNA economy.

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron purchased the pioneering company for $256 million at bankruptcy auction with the intent of using its genomic data to fuel drug discovery, the company said in a Monday statement.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a Top Pick.

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from ...

Regeneron and 23andMe insisted that customers' data would remain in safe hands following the purchase. Skip to content. All Sections. Subscribe Now. 75°F. Sunday, June 22nd 2025 ...

As per Niamh Brodie-Machura, Co-Chief Investment Officer at Fidelity International, the effect of tariffs is expected to shift […] We recently published a list of 10 Worst Blue Chip Stocks to Buy.